Celea Therapeutics is speaking with regulators about launching a Phase III trial of its idiopathic pulmonary fibrosis (IPF) drug deupirfenidone after a Phase IIb open-label extension (OLE) success. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback